Skip Navigation



Journal of the National Cancer Institute Advance Access published online on November 27, 2007
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djm234
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/23/1739    most recent
djm234v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rhim, J. H.
Right arrow Articles by Tosato, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rhim, J. H.
Right arrow Articles by Tosato, G.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2007.

EDITORIALS

Targeting the Tumor Vasculature to Improve the Efficacy of Oncolytic Virus Therapy

Jung Hyo Rhim, Giovanna Tosato

Affiliation of authors: Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Correspondence to: Giovanna Tosato, Bldg 37, Rm 4124, Bethesda, MD 20892 (e-mail: tosatog@mail.nih.gov).

The first 10% of the full text of this article appears below.

Virus-mediated oncolysis is not a new concept. The idea goes back to the early 1900s, when it was noted that a flu-like disease coincided with a substantial drop in the number of tumor cells in a leukemic patient (1) and that rabies vaccination was followed by regression of cervical cancer (2). Additional anecdotal observations followed, but early attempts at viral therapy for cancer were unsuccessful (3,4). In principle, to be an effective weapon against cancer, an oncolytic virus must infect and kill cancer cells while sparing normal cells (5,6). Recent advances in biochemistry, molecular biology, and genetic engineering have brought oncolytic virus therapy back into focus. Some viruses that preferentially infect tumor cells . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy
Kazuhiko Kurozumi, Jayson Hardcastle, Roopa Thakur, Ming Yang, Gregory Christoforidis, Giulia Fulci, Fred H. Hochberg, Ralph Weissleder, William Carson, E. Antonio Chiocca, and Balveen Kaur
J Natl Cancer Inst 2007 99: 1768-1781. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 1737. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. Kottke, J. Thompson, R. M. Diaz, J. Pulido, C. Willmon, M. Coffey, P. Selby, A. Melcher, K. Harrington, and R. G. Vile
Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2
Clin. Cancer Res., January 15, 2009; 15(2): 561 - 569.
[Abstract] [Full Text] [PDF]